Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa First-in-Human Study of [212Pb]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Tumors

NCT05636618 is registered in ClinicalTrials.gov with Perspective Therapeutics as lead sponsor.

NCT NCT05636618
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05636618 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa First-in-Human Study of [212Pb]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Tumors
Lead sponsor
Perspective Therapeutics
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 27, 2023
Completion date
December 26, 2029
Enrollment
300 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

bronchial neuroendocrine tumor, gastroenteropancreatic neuroendocrine tumor, meningioma, neuroendocrine tumor metastatic, neuroendocrine tumors unresectable, paraganglioma, pheochromocytoma